# 2025年11月6日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 憩室炎综述

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41191365](https://pubmed.ncbi.nlm.nih.gov/41191365)
**期刊：** JAMA
**PMID：** 41191365
**DOI：** 10.1001/jama.2025.17208

### 第一部分 原文与翻译

**英文原标题：** Review on Diverticulitis.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是发表于《美国医学会杂志》（JAMA）上的一篇关于憩室炎的综述。鉴于其发表在顶级医学期刊，该综述很可能对憩室炎的病理生理、诊断标准、治疗方案及前沿进展进行了全面而权威的总结。然而，由于摘要缺失，我们无法获知其具体的核心观点、证据综合方法及关键结论，这限制了对其具体学术贡献和临床指导价值的深入评估。

---

## 2. 人物专访Esther Obeng：解答未知问题令人兴奋不已

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41191030](https://pubmed.ncbi.nlm.nih.gov/41191030)
**期刊：** The Journal of experimental medicine
**PMID：** 41191030
**DOI：** 10.1084/jem.20252212

### 第一部分 原文与翻译

**英文原标题：** Esther Obeng: It's exciting to tackle questions that don't yet have answers.

**英文摘要原文：**
Esther Obeng is an attending physician and associate professor at Emory University School of Medicine, where she leads a research group focused on myelodysplastic syndromes (MDS). Esther's team is investigating how normal hematopoietic stem cells develop into cancerous cells, as well as developing targeted therapies for MDS patients. We recently spoke to Esther about her move from St. Jude Children's Research Hospital to Emory, how her patients inform her research, as well as the joys and struggles of having running as a hobby.

**中文摘要译文：**
Esther Obeng是埃默里大学医学院的主治医师兼副教授，她在此领导一个专注于骨髓增生异常综合征（MDS）的研究团队。Esther的团队正在研究正常造血干细胞如何演变为癌细胞，并致力于为MDS患者开发靶向疗法。我们最近与Esther进行了对话，谈及她从圣犹大儿童研究医院到埃默里大学的职业变动，她的患者如何为她的研究带来启发，以及将跑步作为一项爱好的乐趣与挑战。

### 第二部分 AI 大师评价

该文并非一篇原创性研究论文，而是一篇人物专访，介绍了埃默里大学医学院的Esther Obeng医师。文章重点展示了她在骨髓增生异常综合征（MDS）领域的研究工作，特别是其团队致力于探索正常造血干细胞向癌细胞转化的机制，并开发相应的靶向治疗方法。这篇专访的价值在于揭示了一位杰出医师科学家的心路历程，强调了临床观察对基础研究的启发作用，为读者提供了一个连接临床实践与前沿科研的生动范例。

---

## 3. KLF9通过抑制NR4A1-p38 MAPK肝脏代谢轴驱动间歇性缺氧诱导的非酒精性脂肪性肝病

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41190983](https://pubmed.ncbi.nlm.nih.gov/41190983)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41190983
**DOI：** 10.1097/HEP.0000000000001606

### 第一部分 原文与翻译

**英文原标题：** KLF9 drives intermittent hypoxia-induced NAFLD by suppressing the NR4A1-p38 MAPK hepatic metabolic axis.

**英文摘要原文：**
BACKGROUND AND AIMS: Obstructive sleep apnea (OSA), characterized by recurrent episodes of intermittent hypoxia (IH), is increasingly as a contributor to metabolic disorders, including non-alcoholic fatty liver disease (NAFLD). However, the causal relationship and underlying molecular mechanisms linking to IH and NAFLD remain incompletely understood, hindering the development of effective therapeutic strategies.

APPROACH AND RESULTS: We established murine and cellular models of IH and performed comprehensive metabolic and molecular profiling, including glucose and insulin tolerance tests, biochemical analyses, histology, lipidomics, RT-qPCR, Western blotting, RNA sequencing, ChIP sequencing, ChIP assay, co-immunoprecipitation, and luciferase reporter gene assays, to investigate the impact of IH and the role of KLF9 in hepatic lipid metabolism. The findings showed IH exposure induced hepatic lipid accumulation and insulin resistance in both normal and obese mice, accompanied by transcriptional reprogramming of lipid metabolic pathways. Transcriptomic analysis identified KLF9 as significantly upregulated by IH treatment. Functional studies demonstrated that hepatic overexpression of KLF9 exacerbated, while its knockdown alleviated, IH-induced steatosis, lipogenesis, and inflammation. Mechanistically, KLF9 directly bound to a conserved GC-rich motif within the NR4A1 promoter, suppressing NR4A1 transcription and downstream p38 MAPK activation. Pharmacologic modulation of NR4A1 further confirmed its regulatory role in mediating KLF9-driven lipogenesis under IH.

CONCLUSIONS: This study identifies KLF9 as a key transcriptional regulator driving IH-associated NAFLD by repressing NR4A1 and inhibiting p38 MAPK signaling, thereby promoting hepatic lipogenesis. Targeting the KLF9-NR4A1 axis may offer a novel therapeutic approach for managing NAFLD in patients with OSA and other hypoxia-related disorders.

**中文摘要译文：**
背景与目的：阻塞性睡眠呼吸暂停（OSA）以反复发作的间歇性缺氧（IH）为特征，日益被认为是包括非酒精性脂肪性肝病（NAFLD）在内的代谢性疾病的一个促成因素。然而，连接IH与NAFLD的因果关系及其潜在分子机制仍未被完全阐明，这阻碍了有效治疗策略的开发。

方法与结果：我们建立了IH的小鼠和细胞模型，并进行了全面的代谢和分子谱分析，包括葡萄糖和胰岛素耐量试验、生化分析、组织学检查、脂质组学、RT-qPCR、蛋白质印迹、RNA测序、ChIP测序、ChIP实验、共免疫沉淀和荧光素酶报告基因检测，以研究IH对肝脏脂质代谢的影响以及KLF9在其中的作用。研究结果显示，IH暴露在正常和肥胖小鼠中均诱导了肝脏脂质积累和胰岛素抵抗，并伴有脂质代谢通路的转录重编程。转录组学分析发现，KLF9在IH处理后显著上调。功能性研究表明，肝脏中过表达KLF9会加剧IH诱导的肝脂肪变性、脂肪生成和炎症，而敲低KLF9则能减轻这些病变。机制上，KLF9直接与NR4A1启动子内一个保守的富含GC的基序结合，从而抑制NR4A1的转录及其下游p38 MAPK的激活。对NR4A1的药物调节进一步证实了其在介导IH条件下KLF9驱动的脂肪生成中的调控作用。

结论：本研究确定了KLF9是驱动IH相关NAFLD的关键转录调节因子，它通过抑制NR4A1并抑制p38 MAPK信号通路来促进肝脏脂肪生成。靶向KLF9-NR4A1轴可能为治疗OSA及其他缺氧相关疾病患者的NAFLD提供一种新的治疗方法。

### 第二部分 AI 大师评价

本研究旨在阐明阻塞性睡眠呼吸暂停（OSA）核心特征——间歇性缺氧（IH）——引发非酒精性脂肪性肝病（NAFLD）的分子机制。研究者通过构建精密的动物与细胞模型，并综合运用转录组学、ChIP-seq等前沿技术，创新性地揭示了KLF9是驱动IH相关NAFLD的关键转录因子。其核心发现是，IH通过上调KLF9，进而抑制NR4A1-p38 MAPK肝脏代谢轴，最终促进肝脏脂肪生成。这项工作不仅深化了对OSA与NAFLD关联的病理生理学理解，也为开发针对OSA患者NAFLD的靶向治疗策略（如靶向KLF9-NR4A1轴）提供了重要的实验依据和新颖思路。

---

## 4. 髓母细胞瘤荟萃分析门户支持对患者临床与基因组数据的整合探索

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41190809](https://pubmed.ncbi.nlm.nih.gov/41190809)
**期刊：** Cancer research
**PMID：** 41190809
**DOI：** 10.1158/0008-5472.CAN-24-4976

### 第一部分 原文与翻译

**英文原标题：** The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients.

**英文摘要原文：**
UNLABELLED: Medulloblastoma is a prevalent, highly heterogeneous malignant pediatric brain cancer. In this study, we developed the Medulloblastoma Meta-Analysis portal, a web-based data analysis and visualization platform that consolidates clinical, molecular, and survival data of 898 patients from three major clinical trials (ACNS0331, ACNS0332, and SJMB03). The portal integrated clinical data with genomic mutations and DNA methylomes, enabling in-depth analyses of tumor subgroups and survival outcomes. Dynamic exploration and custom stratification of these data were made possible by the portal's user-friendly visualization tools powered by the ProteinPaint framework, allowing users to select from a wide range of variables or customize their own. The Cox regression analysis tool in the portal demonstrated utility in examining the prognostic impact of variables across a heterogeneous dataset. Additionally, an in-depth exploration of medulloblastomas that harbor KBTBD4 mutations and their corresponding methylomes generated leads that could help improve molecular classification. These use cases underscore the portal's utility in enhancing risk stratification, informing tailored therapeutic strategies, and revealing the complexities of molecular heterogeneity in patients with medulloblastoma. The portal, along with links to the tutorials and live figures, is freely available at https://viz.stjude.cloud/st-jude-childrens-research-hospital/visualization/medulloblastoma-integrative-analysis-portal~2882.

SIGNIFICANCE: The MB-meta portal facilitates risk stratification of patients using molecular, genomic, clinical, and demographic data, representing a significant step in neuro-oncology data sharing by offering an intuitive web-based platform for complex analyses.

**中文摘要译文：**
无标签：髓母细胞瘤是一种常见的、高度异质性的儿童恶性脑肿瘤。在本研究中，我们开发了髓母细胞瘤荟萃分析门户，这是一个基于网络的数据分析和可视化平台，整合了来自三项主要临床试验（ACNS0331、ACNS0332和SJMB03）的898名患者的临床、分子和生存数据。该门户将临床数据与基因组突变和DNA甲基化组相结合，从而能够对肿瘤亚组和生存结局进行深入分析。该门户借助ProteinPaint框架支持的用户友好型可视化工具，实现了对这些数据的动态探索和自定义分层，允许用户从众多变量中进行选择或自定义变量。门户中的Cox回归分析工具在检验不同变量在异质性数据集中的预后影响方面显示了其效用。此外，对携带KBTBD4突变的髓母细胞瘤及其相应甲基化组的深入探索为改善分子分型提供了线索。这些用例凸显了该门户在加强风险分层、为个体化治疗策略提供信息以及揭示髓母细胞瘤患者分子异质性复杂性方面的实用价值。该门户以及相关教程和实时图表的链接可在 https://viz.stjude.cloud/st-jude-childrens-research-hospital/visualization/medulloblastoma-integrative-analysis-portal~2882 免费获取。

研究意义：髓母细胞瘤荟萃分析门户利用分子、基因组、临床和人口统计学数据促进了患者的风险分层，通过提供一个直观的、基于网络的复杂分析平台，代表了神经肿瘤学数据共享领域的重要一步。

### 第二部分 AI 大师评价

本研究的核心贡献在于开发并推出了一个名为“髓母细胞瘤荟萃分析门户”的开放式网络平台。该平台成功整合了三大临床试验中近900名患者的临床、基因组及生存等多维度数据，并内置了先进的可视化与Cox回归分析工具。研究不仅展示了该门户在动态探索数据、评估预后因素（如KBTBD4突变）方面的强大功能，更重要的是，它极大地推动了神经肿瘤学领域的数据共享与协作。其创新价值在于将复杂的多组学数据分析变得直观易用，为全球研究者提供了一个宝贵的资源，有望加速髓母细胞瘤的风险分层优化和个体化治疗策略的制定。

---

## 5. 乳酸化修饰通过促进DNA非同源末端连接增强乳酸脱氢酶A活性并推动肺腺癌对顺铂的化学耐药性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41190808](https://pubmed.ncbi.nlm.nih.gov/41190808)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41190808
**DOI：** 10.1002/advs.202510733

### 第一部分 原文与翻译

**英文原标题：** Lactylation Enhances the Activity of Lactate Dehydrogenase A and Promotes the Chemoresistance to Cisplatin Through Facilitating DNA Nonhomologous End Junction in Lung Adenocarcinoma.

**英文摘要原文：**
Lactylation is a novel post-translational modification closely related to the glycolytic process, but the regulatory mechanisms between lactylation and glycolysis are far from being elucidated. Lactate dehydrogenase A (LDHA) catalyzes the formation of lactate, which provides the modifying group for protein lactylation. However, whether lactylation occurs on LDHA itself remains unknown. Here, it is found that lactylation promotes the enzymatic activity of LDHA in lung adenocarcinoma (LUAD), which in turn enhances the overall level of cellular lactylation through a positive feedback loop. Screening identified Lys81 and Lys318 as key LDHA lactylation sites, with alanyl-tRNA synthetase 1 (AARS1) serving as the mediating lactyltransferase. Mass spectrometry reveals that numerous proteins involved in DNA nonhomologous end junction (NHEJ), including FEN1, XRCC5, and XRCC6 might be regulated by lactylation. Delactylation of these proteins significantly hinders the formation of FEN1-RAD1-RAD9A-HUS1 complex, thereby leading to dysfunction of NHEJ and increasing the sensitivity of cancer cells to cisplatin. In summary, this work identifies LDHA lactylation as a critical mechanism for accelerating the progression of LUAD and reveals how this lactylation influenced cisplatin sensitivity of LUAD cells, which deepen the understanding of lactylation-mediated tumor progression and provide a potential new anticancer strategy.

**中文摘要译文：**
乳酸化是一种与糖酵解过程密切相关的新型翻译后修饰，但乳酸化与糖酵解之间的调控机制尚远未阐明。乳酸脱氢酶A（LDHA）催化乳酸的形成，而乳酸为蛋白质乳酸化提供修饰基团。然而，LDHA自身是否发生乳酸化修饰仍是未知的。本研究发现，在肺腺癌（LUAD）中，乳酸化能促进LDHA的酶活性，进而通过正反馈循环提高细胞整体的乳酸化水平。筛选鉴定出Lys81和Lys318是LDHA的关键乳酸化位点，并发现丙氨酰-tRNA合成酶1（AARS1）是介导该过程的乳酸化转移酶。质谱分析显示，许多参与DNA非同源末端连接（NHEJ）的蛋白质，包括FEN1、XRCC5和XRCC6，可能受到乳酸化的调控。这些蛋白质的去乳酸化会显著阻碍FEN1-RAD1-RAD9A-HUS1复合物的形成，从而导致NHEJ功能障碍，并增加癌细胞对顺铂的敏感性。综上所述，本研究将LDHA乳酸化确定为加速LUAD进展的关键机制，并揭示了该乳酸化如何影响LUAD细胞的顺铂敏感性，这加深了对乳酸化介导的肿瘤进展的理解，并提供了一种潜在的新型抗癌策略。

### 第二部分 AI 大师评价

本研究旨在探讨乳酸脱氢酶A（LDHA）自身的乳酸化修饰在肺腺癌（LUAD）进展和化疗耐药中的作用机制。研究通过质谱分析和功能实验，首次发现LDHA的乳酸化能以正反馈方式增强其自身酶活性和细胞整体乳酸化水平，并进一步揭示了该修饰通过促进DNA非同源末端连接（NHEJ）通路相关蛋白的功能，导致对顺铂的耐药。此项工作创新性地将糖酵解、蛋白质翻译后修饰与DNA损伤修复联系起来，为理解肿瘤代谢重编程与化疗耐药提供了新视角，并提示靶向乳酸化过程可能成为克服LUAD顺铂耐药的新策略。

---

## 6. 更正：利用葡萄糖响应性CRISPR纳米疫苗阻断SMARCAL1的晚期癌症免疫疗法

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41190795](https://pubmed.ncbi.nlm.nih.gov/41190795)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41190795
**DOI：** 10.1002/advs.202520638

### 第一部分 原文与翻译

**英文原标题：** Correction to Advanced Cancer Immunotherapy via SMARCAL1 Blockade Using a Glucose-Responsive CRISPR Nanovaccine.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本篇文献是针对先前发表的一项研究的更正声明。原研究旨在通过一种葡萄糖响应性CRISPR纳米疫苗阻断SMARCAL1，以探索晚期癌症免疫治疗的新途径。该方法巧妙地结合了CRISPR基因编辑、纳米技术与肿瘤微环境响应策略，代表了精准治疗的前沿方向。此更正本身不提供新的研究发现，但对于维护原始研究的科学准确性和完整性至关重要。

---

## 7. T细胞耗竭及树突状细胞对三级淋巴结构的调控影响微卫星稳定型直肠癌的新辅助放化疗疗效

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41190765](https://pubmed.ncbi.nlm.nih.gov/41190765)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41190765
**DOI：** 10.1002/advs.202514332

### 第一部分 原文与翻译

**英文原标题：** T Cell Exhaustion and Dendritic Cell-Mediated Tertiary Lymphoid Structures (TLSs) Modulation Affect Response to Neoadjuvant Chemoradiotherapy in Microsatellite Stable Rectal Cancer.

**英文摘要原文：**
Locally advanced rectal cancer (LARC) presents significant treatment challenges, particularly in microsatellite stable (MSS) patients, who often show limited response to immunotherapy. In these cases, neoadjuvant chemoradiotherapy (neoCRT) followed by surgery remains the recommended approach. However, the response to neoCRT varies significantly among LARC patients. In this study, the role of the tumor microenvironment (TME) is explored, focusing on early-stage exhausted T cells (early-Tex) and tertiary lymphoid structures (TLS), in predicting neoCRT response in MSS LARC. Through multi-omics analyses, it is found that immune features of the TME, rather than mutational status, are more closely associated with treatment response. Within the TME, it is observed that early-Tex cells, a subset with both similarities and distinct differences compared to previously described precursor exhausted T (Tpex) cells, are enriched in responders and correlated with favorable treatment outcomes. Additionally, it is identified that TLSs are more abundant, activated, and mature in responders compared to non-responders. LAMP3⁺ dendritic cells (DCs) play a pivotal role in suppressing TLS formation, with IRF8 as a key transcriptional regulator, which may ultimately affect therapeutic response. These findings suggest early-Tex cells and modulation of TLS by LAMP3⁺ DCs can serve as indicators for optimizing neoCRT in MSS LARC.

**中文摘要译文：**
局部晚期直肠癌（LARC）的治疗面临巨大挑战，尤其是在微卫星稳定（MSS）型患者中，他们通常对免疫治疗反应不佳。在这些病例中，新辅助放化疗（neoCRT）后进行手术切除仍然是推荐的治疗方案。然而，不同LARC患者对neoCRT的反应差异显著。本研究旨在探讨肿瘤微环境（TME）在预测MSS LARC患者对neoCRT反应中的作用，重点关注早期耗竭T细胞（early-Tex）和三级淋巴结构（TLS）。通过多组学分析发现，TME的免疫特征而非突变状态，与治疗反应的关联更为密切。研究观察到，在TME中，早期耗竭T细胞（early-Tex）——一个与既往报道的前体耗竭T细胞（Tpex）既有相似性又存在明显差异的亚群——在治疗有效者中富集，并与良好的治疗结局相关。此外，研究还发现，与无应答者相比，治疗有效者体内的TLSs更为丰富、活化且成熟。LAMP3⁺树突状细胞（DCs）在抑制TLS形成中起着关键作用，其关键转录调节因子为IRF8，这可能最终影响治疗反应。这些发现表明，早期耗竭T细胞以及LAMP3⁺ DCs对TLS的调控可作为优化MSS LARC患者新辅助放化疗的指标。

### 第二部分 AI 大师评价

本研究利用多组学分析方法，深入探究了微卫星稳定型直肠癌的肿瘤微环境特征，旨在寻找预测新辅助放化疗疗效的生物标志物。其核心发现是，治疗有效者富含早期耗竭T细胞，并拥有更成熟的三级淋巴结构（TLSs），而LAMP3+树突状细胞则通过IRF8通路抑制TLS的形成。这项研究的创新之处在于揭示了T细胞耗竭亚群和TLS成熟度在决定治疗反应中的关键作用，为优化该类患者的治疗策略和开发新的免疫调节靶点提供了重要的科学依据。

---

## 8. 一项关于R-MPV-A化学免疫疗法联合或不联合低剂量全脑放疗治疗新诊断原发性中枢神经系统淋巴瘤的多中心随机II期研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41189315](https://pubmed.ncbi.nlm.nih.gov/41189315)
**期刊：** Neuro-oncology
**PMID：** 41189315
**DOI：** 10.1093/neuonc/noaf221

### 第一部分 原文与翻译

**英文原标题：** Multicenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS Lymphoma.

**英文摘要原文：**
BACKGROUND: Methotrexate-based chemoradiotherapy is effective in primary central nervous system lymphoma (PCNSL) but carries a risk of severe neurotoxicity. In a single-arm study, a regimen with methotrexate, procarbazine, vincristine and cytarabine was combined with rituximab (R-MPV-A) and substantially reduced doses of whole-brain radiotherapy (LD-WBRT), resulting in excellent progression-free survival (PFS) and overall survival (OS). Because R-MPV-A had never been tested without radiation, we sought to evaluate the efficacy of R-MPV-A with and without LD-WBRT, as well as determining if such low radiotherapy doses influenced disease control and/or neurotoxicity.

METHODS: Patients were randomized to receive R-MPV-A alone (Chemo arm) or combined with LD-WBRT (ChemoRT arm), given at 2,340 cGy (180cGy X13). Primary endpoint was intent-to-treat (ITT) PFS. A sample size of 89 would provide 80% power to detect a hazard ratio (HR) of 0.63 (one-sided alpha = 0.15).

RESULTS: Ninety-one patients were randomized, with 44 analyzed in the ChemoRT and 46 in the Chemo arm. Median age was 66 and 59.5, respectively. R-MPV-A was well tolerated, achieving complete response rate of 92.3% (ChemoRT) and 76.3% (Chemo). After median follow-up of 4.6 years, median PFS was not reached (ChemoRT) vs 2.1 years (Chemo), HR = 0.47 (p = 0.007; 95% CI: 0.26 to 0.87). The 2-year PFS was 78.7% vs 54%, respectively. Differences in OS did not reach statistical significance (HR 0.71; p = 0.33). Neuropsychological evaluation showed no differences in cognitive outcomes, with several tests favoring ChemoRT.

CONCLUSIONS: R-MPV-A is a highly efficacious and safe regimen with or without LD-WBRT. LD-WBRT contributes to disease control and increases PFS in PCNSL.

**中文摘要译文：**
背景：基于甲氨蝶呤的放化疗对原发性中枢神经系统淋巴瘤（PCNSL）有效，但存在严重神经毒性的风险。在一项单臂研究中，一种包含甲氨蝶呤、丙卡巴肼、长春新碱和阿糖胞苷的方案与利妥昔单抗（R-MPV-A）以及剂量大幅降低的全脑放疗（LD-WBRT）相结合，取得了出色的无进展生存期（PFS）和总生存期（OS）。由于R-MPV-A方案从未在不联合放疗的情况下进行过测试，我们旨在评估R-MPV-A联合及不联合LD-WBRT的疗效，并确定如此低的放疗剂量是否会影响疾病控制和/或神经毒性。

方法：患者被随机分为单独接受R-MPV-A治疗的化疗组或联合LD-WBRT治疗的放化疗组，放疗剂量为2340 cGy（180cGy X 13次）。主要终点是意向性治疗（ITT）人群的无进展生存期（PFS）。样本量为89例时，将有80%的把握检测到0.63的风险比（HR）（单侧α=0.15）。

结果：共91例患者被随机分组，其中44例在放化疗组进行分析，46例在化疗组进行分析。两组的中位年龄分别为66岁和59.5岁。R-MPV-A方案耐受性良好，在放化疗组和化疗组分别实现了92.3%和76.3%的完全缓解率。经过中位4.6年的随访，放化疗组的中位PFS尚未达到，而化疗组为2.1年，风险比（HR）=0.47（p=0.007；95% CI：0.26至0.87）。两组的2年PFS率分别为78.7%和54%。总生存期（OS）的差异未达到统计学显著性（HR 0.71；p=0.33）。神经心理学评估显示，两组在认知结局上没有差异，且有几项测试结果显示放化疗组更优。

结论：无论是否联合LD-WBRT，R-MPV-A都是一种高效且安全的治疗方案。LD-WBRT有助于疾病控制并能延长PCNSL患者的PFS。

### 第二部分 AI 大师评价

本研究通过一项多中心随机II期临床试验，旨在评估R-MPV-A化学免疫疗法联合或不联合低剂量全脑放疗（LD-WBRT）对于新诊断原发性中枢神经系统淋巴瘤（PCNSL）的疗效与安全性。研究的关键发现是，与单纯化疗相比，在R-MPV-A方案基础上增加LD-WBRT能显著延长患者的无进展生存期（PFS），且未增加可观测的认知功能神经毒性。这项研究的价值在于，它为PCNSL的治疗提供了一个重要的循证依据，证实了即便是低剂量的放疗，在现代高效化学免疫疗法背景下，对于改善疾病控制仍然至关重要，有助于在最大化疗效与最小化远期毒性之间取得更优平衡。

---

## 9. CAR-T细胞免疫疗法中基于纳米颗粒的策略：挑战、意义与展望

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41188940](https://pubmed.ncbi.nlm.nih.gov/41188940)
**期刊：** Molecular cancer
**PMID：** 41188940
**DOI：** 10.1186/s12943-025-02476-7

### 第一部分 原文与翻译

**英文原标题：** Nanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该文献从标题判断应为一篇综述或前瞻性文章，旨在系统性探讨将纳米颗粒技术应用于CAR-T细胞免疫疗法中的策略。文章可能重点梳理了当前该交叉领域面临的主要挑战，分析了其潜在的临床意义与深远影响，并对未来发展方向进行了展望。尽管该文可能不包含原创实验数据，但其通过整合现有知识，为该前沿领域的研究者提供了宝贵的参考框架和思路启发，具有重要的学术指导价值。

---

## 10. 基因组不稳定性及其与免疫应答的相互作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41188872](https://pubmed.ncbi.nlm.nih.gov/41188872)
**期刊：** Genome medicine
**PMID：** 41188872
**DOI：** 10.1186/s13073-025-01509-6

### 第一部分 原文与翻译

**英文原标题：** Genome instability and crosstalk with the immune response.

**英文摘要原文：**
Genome instability, tumour-promoting inflammation, and immune escape are three distinct hallmarks of cancer. However, accumulating scientific and clinical evidence over the past decade have uncovered a multifaceted interplay of complex dynamic network of interactions between genome instability, the DNA damage response (DDR), and tumour immunogenicity. Fuelled by the clinical successes of immune checkpoint blockers (ICB), growing interest for immuno-oncology and recent cancer biology discoveries have allowed a better understanding of the underlying biology and clinical opportunities brought by this interplay-which is yet, still only in its infancy. The cooperative nature of tumour cell-intrinsic and -extrinsic mechanisms involved suggests that harnessing genomic instability in cancer does not only hamper cancer cells fitness but also stimulate the anti-tumour immune response, thereby paving the way to the development of DDR-based immunomodulatory therapeutic strategies applicable to a variety of molecular and histological cancer types. Here, we review the various aspects of this crosstalk between genome instability and tumour immunogenicity, including feedforward and feedback mechanisms affecting either side of this interplay, as well as the specific consequences of chromosomal instability. We further discuss emerging DDR-based predictive biomarkers of response to ICB therapies, and finally examine the latest clinical developments of therapeutic combinations that exploit the DDR-immunity interplay in immuno-oncology.

**中文摘要译文：**
基因组不稳定性、肿瘤促进性炎症和免疫逃逸是癌症的三个不同标志。然而，过去十年间积累的科学和临床证据揭示了基因组不稳定性、DNA损伤反应（DDR）与肿瘤免疫原性之间存在着一个由复杂动态网络构成的多方面相互作用。在免疫检查点阻断剂（ICB）临床成功的推动下，人们对肿瘤免疫学的兴趣日益浓厚，加之近期癌症生物学的发现，使得我们对这种相互作用背后的生物学机制及其带来的临床机遇有了更深入的理解——尽管相关研究仍处于起步阶段。所涉及的肿瘤细胞内在和外在机制的协同性质表明，在癌症中利用基因组不稳定性不仅会削弱癌细胞的适应性，还能刺激抗肿瘤免疫反应，从而为开发适用于多种分子和组织学类型癌症的、基于DDR的免疫调节治疗策略铺平了道路。在此，我们综述了基因组不稳定性与肿瘤免疫原性之间相互作用的各个方面，包括影响此相互作用双方的前馈和反馈机制，以及染色体不稳定性的具体后果。我们进一步讨论了新兴的、可预测ICB治疗反应的DDR相关生物标志物，并最后审视了在肿瘤免疫学中利用DDR与免疫相互作用的联合治疗方案的最新临床进展。

### 第二部分 AI 大师评价

本篇综述深刻剖析了基因组不稳定性与抗肿瘤免疫应答之间复杂的相互作用。文章系统性地总结了DNA损伤反应（DDR）如何将基因组不稳定性转化为肿瘤免疫原性，并探讨了其中的前馈与反馈机制。其突出价值在于，不仅整合了该交叉领域的最新认知，还前瞻性地讨论了基于DDR的生物标志物在预测免疫检查点抑制剂疗效中的应用，并展望了靶向DDR以增强免疫治疗的联合策略。这为开发新型抗癌疗法提供了重要的理论依据和临床启示。

---

## 11. SHIP2-PLK1串扰促进食管鳞状细胞癌对双重抑制的敏感性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41188852](https://pubmed.ncbi.nlm.nih.gov/41188852)
**期刊：** Molecular cancer
**PMID：** 41188852
**DOI：** 10.1186/s12943-025-02454-z

### 第一部分 原文与翻译

**英文原标题：** SHIP2-PLK1 crosstalk promotes sensitivity to dual inhibition in esophageal squamous cell carcinoma.

**英文摘要原文：**
BACKGROUND: Drug synergy in cancer therapy has gained attention for its potential to enhance efficacy and minimize adverse effects. Synergy, where the combined effect of drugs exceeds the sum of their individual effects, is beneficial in addressing tumor heterogeneity and drug resistance in oncology. Esophageal squamous cell carcinoma (eSCC), accounting for over 85% of esophageal cancer cases, has a poor prognosis and limited therapeutic options. Targeted therapies have shown inefficiency in eSCC due to resistance mechanisms, making drug combination an interesting option.

METHODS: To investigate new therapeutic startegies in eSCC, we utilized a combination of multiple human eSCC cell lines, xenotransplant models, primary mouse eSCC model, CRISPR/Cas9-based genetic manipulation and RNA sequencing analysis.

RESULTS: We report the role of SHIP2, a phosphoinositide (PI) 5-phosphatase, in eSCC. Amplification of the INPPL1 gene, encoding SHIP2, was prevalent in eSCC, linked to elevated SHIP2 transcript levels. SHIP2 knockdown and pharmacological inhibition demonstrated its influence on eSCC cell survival, proliferation, and adhesion, partially by decreasing AKT phosphorylation and perturbing cell cycle-associated transcripts. SHIP2's impact was not restricted to cells harboring INPPL1 amplification, implying its potential activity across diverse eSCC subtypes. Compensation mechanisms emerged in SHIP2-deficient eSCC cells, highlighting the necessity of combinatory approaches to counteract resistance. RNA sequencing identified PLK1 as a prominent downregulated transcript upon SHIP2 inhibition, revealing synergistic potential with PLK1 inhibitors.

CONCLUSIONS: Our data support the use of specific SHIP2 inhibitors, in combination with PLK1 inhibitors, as a promising strategy for stalling eSCC growth, amplifying treatment response, and circumventing resistance. This study unravels the intricate interplay of SHIP2 within the PI3K/AKT pathway and cell cycle in eSCC, paving the way for targeted interventions with the potential to transform the therapeutic landscape of this challenging malignancy.

**中文摘要译文：**
背景：药物协同作用因其在增强疗效和减少不良反应方面的潜力而在癌症治疗中备受关注。在肿瘤学中，协同作用（即药物的联合效果超过其单独效果的总和）在解决肿瘤异质性和耐药性方面是有益的。食管鳞状细胞癌（eSCC）占食管癌病例的85%以上，其预后差且治疗选择有限。由于耐药机制的存在，靶向治疗在eSCC中效果不佳，这使得药物联合应用成为一个有吸引力的选择。

方法：为探究eSCC的新治疗策略，我们综合运用了多种人类eSCC细胞系、异种移植模型、原代小鼠eSCC模型、基于CRISPR/Cas9的基因编辑技术和RNA测序分析。

结果：我们报道了磷脂酰肌醇（PI）5-磷酸酶SHIP2在eSCC中的作用。编码SHIP2的INPPL1基因的扩增在eSCC中普遍存在，并与SHIP2转录水平的升高相关。通过SHIP2敲低和药物抑制证明了其对eSCC细胞存活、增殖和粘附的影响，其部分机制是通过降低AKT磷酸化水平和干扰细胞周期相关转录本实现的。SHIP2的影响不仅限于携带INPPL1基因扩增的细胞，这表明其可能在多种eSCC亚型中均具有活性。在SHIP2缺陷的eSCC细胞中出现了代偿机制，这凸显了采用联合治疗方法以对抗耐药性的必要性。RNA测序发现，在抑制SHIP2后，PLK1是一个显著下调的转录本，这揭示了其与PLK1抑制剂联合使用的协同潜力。

结论：我们的数据支持将特异性SHIP2抑制剂与PLK1抑制剂联合使用，作为一种有前景的策略，用以抑制eSCC生长、增强治疗反应并规避耐药性。本研究揭示了SHIP2在eSCC中PI3K/AKT通路及细胞周期内的复杂相互作用，为开发靶向干预措施铺平了道路，这些干预措施有潜力改变这种难治性恶性肿瘤的治疗格局。

### 第二部分 AI 大师评价

本研究旨在探究SHIP2在食管鳞状细胞癌（eSCC）中的作用，并基于其机制探索新的联合治疗策略。研究综合运用了细胞、动物模型及RNA测序等技术，发现SHIP2在eSCC中普遍扩增，并通过影响PI3K/AKT通路等促进肿瘤进展。该研究的关键创新在于，揭示了抑制SHIP2会下调PLK1，从而阐明了SHIP2抑制剂与PLK1抑制剂联合应用的协同抗癌机制。这一发现为预后极差的eSCC提供了一个极具潜力的“双靶点”治疗新策略，具有重要的临床转化价值。

---

## 12. 一个超级蛋白质进化引擎。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41188620](https://pubmed.ncbi.nlm.nih.gov/41188620)
**期刊：** Nature chemical biology
**PMID：** 41188620
**DOI：** 10.1038/s41589-025-02065-1

### 第一部分 原文与翻译

**英文原标题：** A super protein evolution engine.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该研究标题“一个超级蛋白质进化引擎”预示了一项关于蛋白质工程突破性技术的报告。虽然摘要缺失，但发表于《自然-化学生物学》这一顶级期刊，暗示该研究可能开发了一种高效、强大的新型蛋白质定向进化系统。此系统有望极大加速功能性蛋白质（如酶、抗体）的筛选与优化过程，在生物医药、合成生物学及工业催化等领域具有巨大的应用潜力和科研价值。

---

## 13. 作者更正：醛缩酶B通过抑制G6PD和磷酸戊糖途径来抑制肝细胞癌的发生

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41188550](https://pubmed.ncbi.nlm.nih.gov/41188550)
**期刊：** Nature cancer
**PMID：** 41188550
**DOI：** 10.1038/s43018-025-01075-1

### 第一部分 原文与翻译

**英文原标题：** Author Correction: Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇作者更正，其原始研究旨在阐明醛缩酶B（Aldolase B）在肝细胞癌发生中的作用机制。根据标题推断，该研究的关键发现是，Aldolase B通过抑制葡萄糖-6-磷酸脱氢酶（G6PD）的活性，进而抑制磷酸戊糖途径，从而发挥其抑制肝细胞癌的肿瘤抑制功能。这项发现揭示了ALDOB在肿瘤代谢重编程中的新角色，为理解肝癌的发生发展提供了新的分子视角，并可能为靶向肿瘤代谢的治疗策略提供潜在靶点。由于原文摘要缺失，无法对具体实验设计和数据进行更深入的评估。

---

## 14. 来自2025年欧洲肿瘤内科学会（ESMO）大会的报道

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41188535](https://pubmed.ncbi.nlm.nih.gov/41188535)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41188535
**DOI：** 10.1038/s41571-025-01101-2

### 第一部分 原文与翻译

**英文原标题：** From the ESMO Congress 2025.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该文献标题表明，这是一篇关于2025年欧洲肿瘤内科学会（ESMO）大会的会议报道或亮点集锦。由于该文献没有提供摘要，因此无法对其具体内容进行深入分析。通常，这类文章的核心价值在于快速总结和传播顶级学术会议中的前沿研究成果与临床试验数据，帮助读者及时了解肿瘤学领域的最新动态和未来发展方向。

---

## 15. 一种靶向急性髓系白血病代谢依赖性的新策略

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41188278](https://pubmed.ncbi.nlm.nih.gov/41188278)
**期刊：** Cell death & disease
**PMID：** 41188278
**DOI：** 10.1038/s41419-025-08129-3

### 第一部分 原文与翻译

**英文原标题：** A novel strategy to target metabolic dependencies in acute myeloid leukemia.

**英文摘要原文：**
Acute myeloid leukemia (AML) remains difficult to cure despite recent advances. Off-target side effects of drugs currently used lead to significant morbidity and mortality. There is recognition that in AML, there is an increased dependence on OXPHOS metabolism, especially in the leukemia stem cell compartment (AML-LSC). It is also recognized that there is potential to exploit this vulnerability to treat AML. Drug re-purposing screens have suggested the potential use of artesunate (ART) to inhibit mitochondrial respiration. We have explored the potential role of ART as an additive agent in treating AML in combination with conventional therapy. Through in-vitro and in-vivo mouse model studies, we demonstrate the mechanism and efficacy of these combinations and their potential to overcome venetoclax resistance. We further demonstrate the specificity of these combinations with minimal off-target effects on normal hematopoietic stem cells (HSC). These observations warrant exploration of the additive role of ART in clinical trials.

**中文摘要译文：**
尽管近期取得了进展，急性髓系白血病（AML）的治愈仍然困难重重。当前所用药物的脱靶副作用导致了显著的发病率和死亡率。已有认识表明，在AML中，尤其是在白血病干细胞（AML-LSC）区室，存在对氧化磷酸化（OXPHOS）代谢日益增长的依赖性。同样，人们也认识到利用这一弱点来治疗AML具有潜力。药物再利用筛选已提示青蒿琥酯（ART）在抑制线粒体呼吸方面具有潜在用途。我们探索了ART作为一种辅助药物，在与常规疗法联合治疗AML中的潜在作用。通过体外及体内小鼠模型研究，我们证实了这些组合的机制和疗效，以及它们克服维奈托克耐药性的潜力。我们进一步证明了这些组合的特异性，其对正常造血干细胞（HSC）的脱靶效应极小。这些观察结果为在临床试验中探索ART的辅助作用提供了充分依据。

### 第二部分 AI 大师评价

该研究旨在探索“老药新用”的策略，将青蒿琥酯（ART）作为一种靶向急性髓系白血病（AML）代谢依赖性的辅助治疗药物。研究通过体外与体内实验证实，ART联合常规疗法能有效抑制AML细胞，克服维奈托克耐药，且对正常造血干细胞毒性低。这项工作的创新之处在于揭示了ART在线粒体呼吸抑制中的新角色，并为AML，特别是耐药性AML，提供了一种具有高特异性和低副作用潜力的联合治疗新思路，为后续的临床转化研究奠定了坚实的实验基础。

---

## 16. 蛋白质层面的批次效应校正可增强质谱蛋白质组学分析的稳健性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41188254](https://pubmed.ncbi.nlm.nih.gov/41188254)
**期刊：** Nature communications
**PMID：** 41188254
**DOI：** 10.1038/s41467-025-64718-y

### 第一部分 原文与翻译

**英文原标题：** Protein-level batch-effect correction enhances robustness in MS-based proteomics.

**英文摘要原文：**
Batch effects, defined as unwanted technical variations caused by differences in labs, pipelines, or batches, are notorious in MS-based proteomics data, wherein protein quantities are inferred from precursor- and peptide-level intensities. However, the optimal stage for batch-effect correction remains elusive and crucial. Leveraging real-world multi-batch data from the Quartet protein reference materials and simulated data, we benchmark batch-effect correction at precursor, peptide, and protein levels combined across two designed scenarios (balanced and confounded), three quantification methods (MaxLFQ, TopPep3, and iBAQ), and seven batch-effect correction algorithms (Combat, Median centering, Ratio, RUV-III-C, Harmony, WaveICA2.0, and NormAE). Our findings reveal that protein-level correction is the most robust strategy, and the quantification process interacts with batch-effect correction algorithms. Furthermore, we extend our analysis to large-scale data from 1431 plasma samples of type 2 diabetes patients in Phase 3 clinical trials, demonstrating the superior prediction performance of the MaxLFQ-Ratio combination. These findings support that batch-effect correction at the protein level enhances multi-batch data integration in large proteomics cohort studies.

**中文摘要译文：**
批次效应，定义为由实验室、分析流程或批次差异引起的非期望技术性变异，在基于质谱的蛋白质组学数据中是众所周知的问题，其中蛋白质的定量是从前体和肽段水平的强度推断出来的。然而，进行批次效应校正的最佳阶段仍然不明确且至关重要。我们利用来自Quartet蛋白质参考物质的真实多批次数据和模拟数据，在两种设计场景（平衡与混杂）、三种定量方法（MaxLFQ、TopPep3和iBAQ）以及七种批次效应校正算法（Combat、中位数中心化、Ratio、RUV-III-C、Harmony、WaveICA2.0和NormAE）的组合下，对前体、肽段和蛋白质水平的批次效应校正进行了基准测试。我们的研究结果表明，蛋白质水平的校正是最稳健的策略，并且定量过程与批次效应校正算法存在交互作用。此外，我们将分析扩展到来自3期临床试验中1431名2型糖尿病患者血浆样本的大规模数据，证明了MaxLFQ与Ratio组合具有卓越的预测性能。这些发现支持了在蛋白质水平进行批次效应校正能够增强大型蛋白质组学队列研究中多批次数据的整合效果。

### 第二部分 AI 大师评价

本研究旨在系统性地解决质谱蛋白质组学中批次效应校正的最佳时机问题。通过对前体、肽段和蛋白质三个层面，结合多种定量方法与校正算法进行全面基准测试，研究明确指出蛋白质水平的校正是最稳健的策略。该研究的关键发现，特别是验证了MaxLFQ-Ratio组合在大型临床队列中的优越性，为处理多批次蛋白质组学数据提供了清晰、实用的指导，极大地提升了大规模队列研究中数据整合的可靠性与可重复性。

---

## 17. 慢性淋巴细胞白血病特异性分析揭示细菌脂多糖是已确定的刻板型BCR亚群的同源配体。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41188252](https://pubmed.ncbi.nlm.nih.gov/41188252)
**期刊：** Blood cancer journal
**PMID：** 41188252
**DOI：** 10.1038/s41408-025-01405-7

### 第一部分 原文与翻译

**英文原标题：** Chronic lymphocytic leukemia specificity analyses unveil bacterial lipopolysaccharides as the cognate ligands of established stereotyped BCR subsets.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究旨在鉴定慢性淋巴细胞白血病（CLL）中特定刻板型B细胞受体（BCR）的同源配体。由于缺乏摘要，仅从标题判断，该研究通过特异性分析，关键性地发现细菌脂多糖（LPS）是这些已确立的BCR亚群的识别对象。该发现具有显著的创新性，它将一种常见的病原体相关分子直接与CLL克隆的抗原识别联系起来，提示慢性感染或炎症在特定CLL亚型的发病与疾病进展中可能扮演着重要的驱动角色。这项工作不仅深化了对CLL发病机制的理解，也为探索新的治疗靶点提供了潜在方向。

---

## 18. 多发性骨髓瘤患者经teclistamab治疗后复发的结局

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41188250](https://pubmed.ncbi.nlm.nih.gov/41188250)
**期刊：** Blood cancer journal
**PMID：** 41188250
**DOI：** 10.1038/s41408-025-01408-4

### 第一部分 原文与翻译

**英文原标题：** Outcomes of relapse after teclistamab therapy in multiple myeloma.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究聚焦于一个新兴且重要的临床问题：接受teclistamab治疗后复发的多发性骨髓瘤患者的临床结局。Teclistamab作为一种新型双特异性抗体，其耐药或复发后的治疗策略尚不明确，因此该研究具有重要的临床指导价值。通过分析这部分患者的预后数据，本研究可能揭示teclistamab的耐药机制，并为后续治疗方案的选择提供关键依据。尽管缺乏摘要信息，但仅从标题即可判断，这项研究旨在填补该领域的重要知识空白，对临床实践和未来研究均有显著的潜在影响。

---

## 19. 范可尼贫血蛋白的缺失导致细胞对溶酶体胞吐作用产生依赖性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41188232](https://pubmed.ncbi.nlm.nih.gov/41188232)
**期刊：** Cell death & disease
**PMID：** 41188232
**DOI：** 10.1038/s41419-025-08164-0

### 第一部分 原文与翻译

**英文原标题：** Loss of Fanconi anemia proteins causes a reliance on lysosomal exocytosis.

**英文摘要原文：**
Mutations in the Fanconi Anemia (FA) pathway lead to a rare genetic disease that increases risk of bone marrow failure, acute myeloid leukemia, and solid tumors. FA patients have a 500 to 800-fold increase in head and neck squamous cell carcinoma compared to the general population and the treatments for these malignancies are ineffective and limited due to the deficiency in DNA damage repair. Using unbiased CRISPR-interference screening, we found the loss of FA pathway function renders cells dependent on key exocytosis genes such as SNAP23. Further investigation revealed that loss of FA pathway function induced deficiencies in lysosomal health, dysregulation of autophagy and increased lysosomal exocytosis. The compromised cellular state caused by the loss of FA genes is accompanied by decreased lysosome abundance and increased lysosomal membrane permeabilization in cells. We found these signatures in vitro across multiple cell types and cell lines and in clinically relevant FA patient cancers. Our findings are the first to connect the FA pathway to lysosomal exocytosis and thus expands our understanding of FA as a disease and of induced dependencies in FA mutant cancers.

**中文摘要译文：**
范可尼贫血（FA）通路的突变会导致一种罕见的遗传性疾病，该疾病会增加骨髓衰竭、急性髓系白血病和实体瘤的风险。与普通人群相比，FA患者的头颈部鳞状细胞癌发病率增加了500至800倍，并且由于DNA损伤修复的缺陷，针对这些恶性肿瘤的治疗效果不佳且选择有限。通过使用无偏见的CRISPR干扰筛选，我们发现FA通路功能的丧失使细胞对关键的胞吐作用基因（如SNAP23）产生依赖。进一步的研究表明，FA通路功能的丧失会引发溶酶体健康缺陷、自噬失调以及溶酶体胞吐作用增加。由FA基因缺失引起的细胞受损状态，伴随着细胞内溶酶体数量的减少和溶酶体膜通透性的增加。我们在多种体外细胞类型和细胞系以及临床相关的FA患者癌症中均发现了这些特征。我们的研究结果首次将FA通路与溶酶体胞吐作用联系起来，从而扩展了我们对FA作为一种疾病的理解，以及对FA突变型癌症中诱导性依赖的认识。

### 第二部分 AI 大师评价

本研究旨在探索范可尼贫血（FA）通路功能丧失所导致的细胞分子层面的后果。研究人员创新性地运用无偏见的CRISPR干扰筛选技术，关键性地揭示了FA通路缺陷会使细胞对溶酶体胞吐作用产生一种“成瘾性”依赖，并伴有溶酶体功能障碍和自噬失调。这项发现首次将DNA损伤修复通路与溶酶体外排功能直接关联，不仅深化了对FA疾病病理生理的理解，更重要的是，它为治疗FA相关的恶性肿瘤（特别是头颈癌）指出了一个全新的、具有潜在价值的治疗靶点。

---

## 20. 亲缘关系密切的大流行性大肠杆菌克隆株之间的基本再生数存在显著差异

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41188230](https://pubmed.ncbi.nlm.nih.gov/41188230)
**期刊：** Nature communications
**PMID：** 41188230
**DOI：** 10.1038/s41467-025-65301-1

### 第一部分 原文与翻译

**英文原标题：** Basic reproduction number varies markedly between closely related pandemic Escherichia coli clones.

**英文摘要原文：**
Extra-intestinal pathogenic Escherichia coli ubiquitously colonize the human gut and represent clinically the most significant bacterial species causing urinary tract infections and bacteremia. During the last two decades clades of the ST131 lineage have spread globally, but it remains unknown how their transmission dynamics compare to the basic reproduction numbers (R) for viral pandemics. We develop a compartmental model for asymptomatic gut colonization and onward transmission coupled with an epidemiological observation model and fit it on the major ST131 clades. Our results indicate that the ST131-A transmission potential (R = 1.47) can be comparable to pandemic influenza viruses, while the significantly lower transmissibility of ST131-C1 (R = 1.18) and ST131-C2 (R = 1.13) suggests that their dissemination has been aided by antibiotic selection pressure and healthcare facilities. Our results provide an advance in understanding the relative transmissibility of these opportunistic pathogens.

**中文摘要译文：**
肠外致病性大肠杆菌广泛定植于人体肠道，是临床上导致尿路感染和菌血症的最主要细菌种类。在过去二十年中，ST131谱系的进化支已在全球蔓延，但其传播动力学与病毒大流行的基本再生数（R）相比如何，目前尚不清楚。我们开发了一个用于无症状肠道定植和后续传播的房室模型，并将其与流行病学观察模型相结合，对主要的ST131进化支进行了拟合。我们的研究结果表明，ST131-A的传播潜力（R = 1.47）可与大流行性流感病毒相媲美，而ST131-C1（R = 1.18）和ST131-C2（R = 1.13）的传播能力则显著较低，这表明它们的传播可能得益于抗生素选择压力和医疗机构的辅助。我们的研究结果为了解这些机会性病原体的相对传播能力提供了新进展。

### 第二部分 AI 大师评价

本研究通过构建创新的流行病学房室模型，首次量化并比较了全球流行的大肠杆菌ST131谱系下不同进化支的基本再生数（R）。研究的核心发现是，ST131-A进化支的传播能力堪比大流行性流感病毒，而ST131-C1和C2的传播则更依赖于抗生素选择和医疗环境等外部因素。这项工作将经典病毒流行病学模型应用于机会性细菌病原体，为理解其传播动态提供了全新的定量视角，对制定精准的医院感染控制和公共卫生策略具有重要指导意义。

---

## 21. Pmt4通过识别底物蛋白富含丝氨酸/苏氨酸区域的两个独立受体位点进行O-甘露糖基化修饰

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/38467729](https://pubmed.ncbi.nlm.nih.gov/38467729)
**期刊：** Nature communications
**PMID：** 38467729
**DOI：** 10.1038/s41467-024-46389-9

### 第一部分 原文与翻译

**英文原标题：** Pmt4 recognizes two separate acceptor sites to O-mannosylate in the S/T-rich regions of substrate proteins.

**英文摘要原文：**
Protein O-mannosyltransferases (PMTs) add mannose to serine/threonine (S/T)-rich proteins in the endoplasmic reticulum, facilitating proper folding and trafficking through the secretory pathway. These enzymes share a conserved architecture that includes a large transmembrane domain housing the catalytic pocket and a lumenal β-trefoil-folded MIR domain. Although S/T-rich regions in acceptor proteins are generally disordered, it remains unclear how PMTs selectively target these regions over other intrinsically disordered sequences. Here, using cryo-EM and X-ray crystallography, we demonstrate that the Saccharomyces cerevisiae Pmt4 dimer recognizes an S/T-rich peptide at two distinct sites. A groove above the catalytic pocket in the transmembrane domain binds the mannose-accepting S/T site, while the lumenal MIR domain engages an S/T-X-S/T motif. Notably, the substrate peptide is simultaneously bound by the catalytic pocket of one Pmt4 protomer and the MIR domain of the other, revealing an unexpected cooperative dual substrate recognition mechanism. This mechanism likely underpins the invariant dimeric architecture observed in all PMT family members.

**中文摘要译文：**
蛋白质O-甘露糖基转移酶（PMTs）在内质网中将甘露糖添加至富含丝氨酸/苏氨酸（S/T）的蛋白质上，从而促进其正确折叠及通过分泌途径的转运。这些酶具有一个保守的结构，包含一个容纳催化口袋的巨大跨膜结构域和一个腔内侧的β-三叶草折叠MIR结构域。尽管受体蛋白中富含S/T的区域通常是无序的，但PMTs如何选择性地靶向这些区域而非其他内在无序序列，目前尚不清楚。在此，我们利用冷冻电子显微镜（cryo-EM）和X射线晶体学技术，证明了酿酒酵母Pmt4二聚体能识别一个富含S/T肽段上的两个不同位点。跨膜结构域中催化口袋上方的一个凹槽结合了接受甘露糖的S/T位点，而腔内侧的MIR结构域则与一个S/T-X-S/T基序结合。值得注意的是，底物肽段同时被一个Pmt4原聚体的催化口袋和另一个原聚体的MIR结构域所结合，揭示了一种出乎意料的协同双重底物识别机制。这一机制很可能解释了在所有PMT家族成员中观察到的恒定二聚体结构。

### 第二部分 AI 大师评价

本研究旨在阐明蛋白质O-甘露糖基转移酶Pmt4选择性识别底物的分子机制。研究团队综合运用冷冻电镜与X射线晶体学等结构生物学方法，关键性地发现Pmt4二聚体通过一种创新的协同双位点模式识别底物：一个原聚体的催化口袋结合糖基化位点，而另一个原聚体的MIR结构域则结合同一底物上的另一特定基序。这一发现不仅巧妙地解释了PMT家族为何保守地以二聚体形式存在，也极大地深化了我们对蛋白质糖基化这一重要翻译后修饰调控机制的理解，为未来可能的相关疾病研究提供了新的结构生物学基础。

---

## 22. HER2DX在老年HER2阳性早期乳腺癌患者中的应用：来自RESPECT试验（曲妥珠单抗±化疗）的扩展随访结果。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41188218](https://pubmed.ncbi.nlm.nih.gov/41188218)
**期刊：** Nature communications
**PMID：** 41188218
**DOI：** 10.1038/s41467-025-65599-x

### 第一部分 原文与翻译

**英文原标题：** HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy.

**英文摘要原文：**
Older adults with HER2-positive early breast cancer are underrepresented in clinical trials, and the benefit of chemotherapy in this population remains uncertain. We evaluated the HER2DX genomic assay within the randomized RESPECT trial (NCT01104935), which compared adjuvant trastuzumab with or without chemotherapy in patients aged 70-80 years. In this prespecified translational analysis (Trans-RESPECT), HER2DX scores were available for 154 patients. The HER2DX risk score classified 74.0% as low risk and 26.0% as high risk. Ten-year relapse-free and overall survival were higher in the low-risk group. HER2DX remained independently associated with overall survival in multivariable analysis. The HER2DX immune, luminal, and proliferation signatures that compose the risk score were also prognostic. While the HER2DX pCR score was not prognostic overall, exploratory subgroup analyses suggested a potential survival benefit from chemotherapy in the pCR-high group. HER2DX offers prognostic value and may guide chemotherapy use in older patients with HER2-positive early breast cancer. Clinical Trial Information NCT01104935.

**中文摘要译文：**
老年HER2阳性早期乳腺癌患者在临床试验中的代表性不足，且化疗在该人群中的获益仍不确定。我们在随机对照试验RESPECT (NCT01104935)中评估了HER2DX基因组检测的价值，该试验在70-80岁的患者中比较了曲妥珠单抗辅助治疗联合或不联合化疗的疗效。在这项预设的转化性研究（Trans-RESPECT）中，我们获得了154名患者的HER2DX评分。HER2DX风险评分将74.0%的患者划分为低风险组，26.0%为高风险组。低风险组的十年无复发生存率和总生存率更高。在多变量分析中，HER2DX仍是总生存率的独立相关因素。构成风险评分的HER2DX免疫、管腔和增殖特征同样具有预后价值。虽然HER2DX pCR评分总体上不具有预后价值，但探索性亚组分析表明，pCR评分高的患者可能从化疗中获得生存获益。HER2DX为老年HER2阳性早期乳腺癌患者提供了预后价值，并可能指导化疗决策。临床试验信息：NCT01104935。

### 第二部分 AI 大师评价

本研究聚焦于临床试验中代表性不足的老年HER2阳性早期乳腺癌患者群体，旨在评估HER2DX基因组检测在其中的预后价值。研究基于RESPECT临床试验的扩展随访数据，创新性地运用基因组学工具来解决老年患者是否应接受化疗这一关键临床问题。核心发现证实，HER2DX风险评分能有效区分患者的复发风险和生存结局，并可能筛选出能从化疗中获益的特定亚组。这项研究为该特殊人群的精准治疗和个体化决策提供了重要证据，具有显著的临床指导意义。

---

## 23. 流感病毒微型核糖核蛋白复合物中聚合酶、核蛋白与RNA的偶联

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41188214](https://pubmed.ncbi.nlm.nih.gov/41188214)
**期刊：** Nature communications
**PMID：** 41188214
**DOI：** 10.1038/s41467-025-64741-z

### 第一部分 原文与翻译

**英文原标题：** Coupling of polymerase-nucleoprotein-RNA in an influenza virus mini ribonucleoprotein complex.

**英文摘要原文：**
Influenza virus ribonucleoprotein complexes (RNPs), composed of the polymerase complex (FluPol), nucleoprotein (NP), and RNA, are essential for replication and transcription. We report atomic-resolution cryo-EM structures of mini-vRNPs in two states: FluPol located inside (State-In) or at the outer rim (State-Out) of the NP-RNA ring. In both states, the 5' and 3' termini of vRNA are bound to FluPol as previously reported. One NP (NP-0) contacts PA/PB1 of FluPol and binds the distal double-stranded vRNA promoter, with its D72-K90 loop inserting into the RNA fork; separated strands occupy NP-0 RNA-binding grooves. Grooves from other NPs form a continuous RNA-protective path, consistent with negative-strand RNA virus mechanisms. In State-In, interfaces for FluPol dimerization or Pol II interaction are blocked, but fully exposed in State-Out. These structures reveal detailed FluPol-NP-RNA coupling and suggest a conformational shift in RNPs during the viral life cycle.

**中文摘要译文：**
流感病毒核糖核蛋白复合物（RNPs）由聚合酶复合物（FluPol）、核蛋白（NP）和RNA组成，对病毒的复制和转录至关重要。我们报告了微型病毒核糖核蛋白复合物（mini-vRNPs）在两种状态下的原子分辨率冷冻电镜（cryo-EM）结构：聚合酶复合物（FluPol）位于NP-RNA环内部（内状态）或外缘（外状态）。在两种状态下，vRNA的5'和3'末端均如先前报道一样与FluPol结合。其中一个核蛋白（NP-0）与FluPol的PA/PB1亚基接触，并结合远端的双链vRNA启动子，其D72-K90环插入RNA分叉处；分开的单链则占据NP-0的RNA结合沟。其他NP的结合沟形成一条连续的RNA保护通路，这与负链RNA病毒的作用机制相符。在内状态下，FluPol二聚化或与Pol II相互作用的界面被阻断，但在外状态下则完全暴露。这些结构揭示了FluPol-NP-RNA之间精细的偶联方式，并提示RNP在病毒生命周期中可能发生构象转变。

### 第二部分 AI 大师评价

本研究利用原子分辨率的冷冻电镜技术，首次解析了流感病毒微型核糖核蛋白复合物（RNP）的两种关键构象状态。研究不仅精细揭示了病毒聚合酶、核蛋白与RNA三者间的详细相互作用模式，还发现这两种状态（内状态与外状态）可能通过构象变化调控聚合酶的二聚化及与宿主因子的互作。这一发现极具创新性，为理解流感病毒复制转录的动态调控机制提供了直接的结构生物学证据，并为开发靶向RNP构象变化的新型抗病毒药物开辟了全新途径。

---

## 24. 关于“口服地西他滨/西达尿苷联合或不联合维奈克拉治疗较高危骨髓增生异常综合征或慢性粒单核细胞白血病的倾向性评分匹配研究”的通讯文章

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41188211](https://pubmed.ncbi.nlm.nih.gov/41188211)
**期刊：** Blood cancer journal
**PMID：** 41188211
**DOI：** 10.1038/s41408-025-01406-6

### 第一部分 原文与翻译

**英文原标题：** Correspondence on: Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文是一篇针对先前发表的关于口服地西他滨/西达尿苷联合维奈克拉治疗较高危骨髓增生异常综合征（MDS）或慢性粒单核细胞白血病（CMML）研究的通讯文章。由于缺乏摘要，无法得知其具体评论内容，但这类文章通常聚焦于原始研究的方法学严谨性、数据解读的准确性或临床实践的启示。其价值在于促进学术对话，对原始研究结果提供补充视角或提出质疑，从而推动该治疗方案在临床应用中的审慎评估和深入理解。

---

## 25. 靶向细胞外基质蛋白Tenascin-C的特异性CAR-T细胞在胶质母细胞瘤临床前模型中可延长生存期

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41188009](https://pubmed.ncbi.nlm.nih.gov/41188009)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41188009
**DOI：** 10.1136/jitc-2024-011382

### 第一部分 原文与翻译

**英文原标题：** Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma.

**英文摘要原文：**
BACKGROUND: Glioblastoma (GBM) is an aggressive brain tumor associated with poor outcome and limited treatment options. Chimeric antigen receptor (CAR) T cells targeting cell surface antigens were shown to induce tumor regression in patients with GBM, although efficacy was transient. To broaden the range of tumor-restricted antigens, we developed CAR T cells targeting Tenascin-C (TNC), a secreted extracellular matrix protein that is overexpressed in GBM and plays a critical role in tumor progression.

METHODS: Second-generation CAR T cells were engineered to target the alternatively spliced fibronectin type III (FNIII)-D domain of TNC using a single-chain variable fragment isolated from the R6N antibody and coupled to a CD28 costimulatory domain. TNC-CAR T cells were evaluated in vitro for antigen specificity, activation, and cell proliferation using TNC-expressing patient-derived GBM cell lines cultured as adherent cells or as neurospheres. Reactivity toward purified TNC protein, tumor supernatant, and ex vivo patient tumor samples was also assessed. Cytotoxic CAR T-cell activity was tested against TNC-positive and TNC-negative GBM cell lines, including bystander effects mediated by secreted TNC. In vivo efficacy and safety were determined in NOD scid gamma mice bearing patient-derived GBM tumors.

RESULTS: TNC-CAR T cells demonstrated activation when exposed to TNC-positive GBM cells, cell-derived supernatants, or purified TNC protein. They exhibited potent cytotoxicity against TNC-expressing, GBM-derived adherent cells and neurospheres, and induced bystander killing of TNC-negative cells in the presence of either TNC-secreting cells or purified TNC. In vivo, TNC-CAR T cells efficiently infiltrated tumors, triggered cancer cell apoptosis, and significantly extended survival of mice bearing patient-derived GBM, with no evidence of off-tumor toxicity. Notably, TNC-CAR T cells were activated exclusively in the presence of tumor samples and showed no reactivity toward patient-derived non-tumor tissues.

CONCLUSIONS: Targeting the alternatively spliced FNIII-D domain of TNC with CAR T cells offers a promising therapeutic approach for GBM. TNC-CAR T cells demonstrated specific tumor recognition, robust antitumor activity and the ability to induce bystander effects mediated by secreted TNC. Their efficacy in preclinical models, combined with a favorable safety profile, underscores their potential for clinical translation.

**中文摘要译文：**
背景：胶质母细胞瘤（GBM）是一种侵袭性脑肿瘤，预后差且治疗选择有限。靶向细胞表面抗原的嵌合抗原受体（CAR）T细胞已被证明可在GBM患者中诱导肿瘤消退，但其疗效是短暂的。为拓宽肿瘤局限性抗原的范围，我们开发了靶向Tenascin-C（TNC）的CAR-T细胞；TNC是一种在GBM中过表达并在肿瘤进展中起关键作用的分泌性细胞外基质蛋白。

方法：我们构建了第二代CAR-T细胞，该细胞利用从R6N抗体中分离并与CD28共刺激域偶联的单链可变片段，靶向TNC的可变剪接纤连蛋白III型（FNIII）-D结构域。我们使用培养为贴壁细胞或神经球的表达TNC的患者来源GBM细胞系，在体外评估了TNC-CAR T细胞的抗原特异性、活化和细胞增殖能力。同时，我们还评估了其对纯化的TNC蛋白、肿瘤上清液和离体患者肿瘤样本的反应性。我们测试了CAR-T细胞对TNC阳性和TNC阴性GBM细胞系的细胞毒活性，包括由分泌型TNC介导的旁观者效应。我们在荷载患者来源GBM肿瘤的NOD scid gamma小鼠中确定了其体内疗效和安全性。

结果：当接触TNC阳性的GBM细胞、细胞衍生的上清液或纯化的TNC蛋白时，TNC-CAR T细胞表现出活化。它们对表达TNC的GBM来源的贴壁细胞和神经球表现出强大的细胞毒性，并在存在分泌TNC的细胞或纯化TNC的情况下，诱导了对TNC阴性细胞的旁观者杀伤效应。在体内，TNC-CAR T细胞能有效浸润肿瘤，触发癌细胞凋亡，并显著延长荷载患者来源GBM的小鼠的生存期，且未发现脱靶毒性证据。值得注意的是，TNC-CAR T细胞仅在存在肿瘤样本时被激活，对患者来源的非肿瘤组织无反应性。

结论：利用CAR-T细胞靶向TNC的可变剪接FNIII-D结构域为GBM提供了一种有前景的治疗方法。TNC-CAR T细胞展示了特异性的肿瘤识别能力、强大的抗肿瘤活性以及诱导由分泌型TNC介导的旁观者效应的能力。它们在临床前模型中的疗效及其良好的安全性，凸显了其临床转化的潜力。

### 第二部分 AI 大师评价

本研究创新性地将CAR-T疗法的靶点从传统的细胞表面抗原拓展至细胞外基质蛋白Tenascin-C（TNC），旨在为治疗侵袭性胶质母细胞瘤（GBM）开辟新途径。研究通过构建靶向TNC特异性结构域的第二代CAR-T细胞，在体外及患者来源的异种移植小鼠模型中证实了其强大的抗肿瘤活性与高度的肿瘤特异性。其关键发现不仅在于CAR-T细胞能有效杀伤TNC阳性细胞，更在于能通过可溶性TNC介导旁观者效应，清除TNC阴性细胞，这对于应对GBM的高度异质性具有重要意义。该策略在临床前研究中展现出显著疗效和良好安全性，为治疗实体瘤提供了极具临床转化潜力的思路。

---

## 26. TRYBECA-1：一项关于Eryaspase联合化疗对比单纯化疗作为晚期胰腺癌二线治疗的随机III期研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41187298](https://pubmed.ncbi.nlm.nih.gov/41187298)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41187298
**DOI：** 10.1200/JCO-25-00872

### 第一部分 原文与翻译

**英文原标题：** TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.

**英文摘要原文：**
PURPOSE: This phase III (ClinicalTrials.gov identifier: NCT03665441) study evaluated eryaspase in combination with chemotherapy as second-line treatment in advanced pancreatic ductal adenocarcinoma (PDAC).

PATIENTS AND METHODS: TRYBECA-1 enrolled patients 18 years and older whose disease progressed on or after 1L chemotherapy. Patients were randomly assigned to eryaspase plus chemotherapy (gemcitabine/nab-paclitaxel or fluorouracil [5-FU], leucovorin [LV], and irinotecan/nanoliposomal irinotecan) or chemotherapy. Treatment was administered in a 4-week cycle for each of the following drugs until disease progression or unacceptable toxicity: eryaspase 100 U/kg intravenously on days 1 and 15; gemcitabine 1,000 mg/m and nab-paclitaxel 125 mg/m intravenously on days 1, 8 and 15; irinotecan 180 mg/m (or nanoliposomal irinotecan 70 mg/m) intravenously on days 1 and 15; 5-FU 2,400 mg/m as one 46-hour infusion (with a bolus of 400 mg/m); and LV 400 mg/m intravenously on days 1 and 15. The primary end point was overall survival (OS); secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety.

RESULTS: A total of 512 patients were randomly assigned (n = 255 for eryaspase and n = 257 for chemotherapy alone). Baseline characteristics were balanced between the two groups. There were 420 deaths, with a median OS of 7.5 months for eryaspase and chemotherapy versus 6.7 months for chemotherapy (hazard ratio [HR], 0.92 [95% CI, 0.76 to 1.11];  = .374); the median PFS was 3.7 months versus 3.4 months (HR, 0.88 [95% CI, 0.73 to 1.07];  = .196), and the ORR was 16.1% versus 12.5% (odds ratio, 1.35; [95% CI, 0.81 to 2.24]), respectively. Grade ≥3 adverse events (AEs) included neutropenia (25.4%  20.3%), asthenia (16.9%  13.8%), and anemia (17.3%  12.2%) in the experimental versus control arms, respectively.

CONCLUSION: The addition of eryaspase to chemotherapy did not improve OS, PFS, or ORR. AEs were generally consistent with previous reports of chemotherapy. These results do not support additional development of eryaspase in PDAC.

**中文摘要译文：**
目的：这项III期研究（ClinicalTrials.gov标识符：NCT03665441）旨在评估Eryaspase联合化疗作为晚期胰腺导管腺癌（PDAC）二线治疗的疗效。

患者与方法：TRYBECA-1研究招募了年龄≥18岁、在一线化疗期间或之后出现疾病进展的患者。患者被随机分配至Eryaspase联合化疗组（吉西他滨/白蛋白紫杉醇 或 氟尿嘧啶[5-FU]、亚叶酸钙[LV]和伊立替康/纳米脂质体伊立替康）或单纯化疗组。治疗以4周为一个周期，直至疾病进展或出现不可接受的毒性：Eryaspase 100 U/kg，在第1、15天静脉注射；吉西他滨 1,000 mg/m² 和白蛋白紫杉醇 125 mg/m²，在第1、8、15天静脉注射；伊立替康 180 mg/m²（或纳米脂质体伊立替康 70 mg/m²），在第1、15天静脉注射；5-FU 2,400 mg/m² 作为一次46小时输注（推注400 mg/m²）；以及LV 400 mg/m²，在第1、15天静脉注射。主要终点是总生存期（OS）；次要终点包括无进展生存期（PFS）、客观缓解率（ORR）和安全性。

结果：共512名患者被随机分配（Eryaspase组 n = 255，单纯化疗组 n = 257）。两组的基线特征均衡。共发生420例死亡事件，Eryaspase联合化疗组的中位OS为7.5个月，而单纯化疗组为6.7个月（风险比[HR], 0.92 [95% CI, 0.76至1.11]; P = .374）；中位PFS分别为3.7个月对3.4个月（HR, 0.88 [95% CI, 0.73至1.07]; P = .196），ORR分别为16.1%对12.5%（比值比, 1.35; [95% CI, 0.81至2.24]）。在试验组与对照组中，≥3级的不良事件（AEs）分别包括中性粒细胞减少症（25.4% vs 20.3%）、乏力（16.9% vs 13.8%）和贫血（17.3% vs 12.2%）。

结论：在化疗基础上加用Eryaspase并未改善OS、PFS或ORR。不良事件与以往化疗报道基本一致。这些结果不支持在PDAC中对Eryaspase进行进一步开发。

### 第二部分 AI 大师评价

本研究是一项旨在评估创新药物Eryaspase联合标准化疗用于晚期胰腺癌二线治疗效果的III期随机对照试验。研究设计严谨，通过对比联合用药与单纯化疗，直接检验新药的附加价值。然而，研究结果明确显示，Eryaspase的加入并未在总生存期、无进展生存期及客观缓解率等关键疗效指标上带来显著获益。因此，尽管该研究在探索胰腺癌治疗新策略上具有积极意义，其阴性结果为该药物在此领域的进一步研发画上了句号，为后续的临床研究提供了重要的循证依据。

---

速递结束，祝您工作愉快！